BrainZell

Name

BrainZell

Website

https://brainzell.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

CNS Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAAAIAJ

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAIAE

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAGAD

Organoids & Organ-on-Chip (regenerative models)

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLAAAIAK

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Brain organoid drug discovery
• CNS drug screening
• AI-native drug discovery
• Neuroinflammation modeling
• IPSC-derived brain models

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Brain Organoid Drug Discovery Services: BrainZell provides drug discovery services to pharmaceutical and biotech companies using their AI-native brain organoid platform. The platform enables high-throughput testing of drug candidates on physiologically relevant human brain models for CNS drug development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BrainZell provides an AI-native drug discovery platform built on high-throughput human brain organoids derived from induced pluripotent stem cells (iPSCs). The platform delivers CNS drug discovery services—including neuroinflammation modeling, efficacy and side-effect testing, and predictive analytics—to pharmaceutical and biotechnology customers developing brain therapies. Integrated neuroimmune components such as microglia co-culture and automated robotic production differentiate the offering from conventional organoid services.

Product overview

BrainZell offers a unified AI-native drug discovery platform centered on high-throughput brain organoids derived from induced pluripotent stem cells (iPSCs). The platform integrates organoid experimentation with advanced computational modeling and AI-driven analysis. Key offerings include human brain organoids with neuroimmune systems, biological mapping for drug efficacy/safety assessment, and customized iPSC sourcing services. The company also offers specialized neuroinflammation models in collaboration with bit.bio. All components are delivered through a single integrated platform rather than separate modules.

Differentiator

Problem solved

Functional benefit

Products and services

• AI-Native Brain Therapy Platform BrainZell's core drug discovery platform combining high-throughput brain organoid experiments derived from iPSCs with advanced computational modeling and integrated AI systems. It is designed to accelerate discovery and development of brain therapies using patient-derived brain organoids and is sold to pharmaceutical and biotechnology customers.
• Human Brain Organoids High-throughput brain organoids derived from induced pluripotent stem cells (iPSCs) that closely mimic human neural biology and include key components of the brain's immune system. Produced in automated robotic labs with capacity for >10,000 tests per week, intended for pharma and biotech customers performing CNS drug discovery.
• iPSC Sourcing Services Customized hiPSC sourcing service offering biobank-derived iPSCs with diverse genetic backgrounds, bespoke iPSCs from clinical partners, and supplied iPSC lines from collaborating partners. Available to pharma, biotech, and academic customers building human-relevant brain disease models.
• Human 3D Neuroinflammation Model with bit.bio ioMicroglia A 3D human neuroinflammation model integrating bit.bio ioMicroglia into BrainZell brain organoids, capturing key neuroimmune features such as IBA1-positive microglial integration, LPS-induced TNF-α and IL-6 responses, and dexamethasone-sensitive suppression of inflammatory activation. Supports neuroinflammatory mechanism studies, immunomodulatory drug screening, and CNS neurosafety assessment for pharma/biotech customers.

Quantifiable outcome

• Platform captures key neuroimmune features including IBA1-positive microglial integration, LPS-induced TNF-α and IL-6 responses, and dexamethasone-sensitive suppression of inflammatory activation

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• bit.biocoreStrategic or Co-development Partner · 10 May 2026BrainZell and bit.bio entered a strategic collaboration to demonstrate integration of bit.bio's ioMicroglia into BrainZell human 3D brain organoids for modeling neuroinflammation in vitro. The collaboration produced a joint application note demonstrating the model's capability to capture key neuroimmune features including microglial integration and inflammatory responses, supporting studies of neuroinflammatory mechanisms, immunomodulatory drug screening, and CNS neurosafety assessment.
• The Johns Hopkins UniversityminorOthersTalent sourcing partnership - BrainZell's platform was built by top talent from institutions including Johns Hopkins University, representing a source of scientific expertise and personnel for the company.
• Karolinska InstituteminorOthersTalent sourcing partnership - BrainZell's platform was built by top talent from institutions including Karolinska Institute, representing a source of scientific expertise and personnel for the company.
• AstraZenecaminorOthersTalent sourcing partnership - BrainZell's platform was built by top talent from institutions including AstraZeneca, representing a source of scientific expertise and personnel for the company.

Scale indicators3 records

Recent moves5 records

Broad incumbents

• Insitro: Machine-learning-driven drug discovery company combining human data, disease models and AI for pharma partnerships — comparable on AI/ML-enabled biology-to-therapeutics model, though Insitro is broader and well-capitalized.
• Emulate: US organ-on-chip company with broader (non-CNS-specific) human-relevant tissue platforms for pharma — comparable in category (organ-on-chip for drug discovery) but broader in therapeutic scope than BrainZell.
• Bio-Techne (Tocris): Large life-science tools and reagents supplier (including Tocris neuroscience reagents) serving pharma and academic CNS research — comparable customer base and CNS positioning, but offers catalog reagents rather than custom organoid services.
• Recursion: AI-native drug discovery company combining high-throughput biology with machine learning to discover therapeutics — comparable on the AI-native lab-in-the-loop thesis, though Recursion operates at far greater scale and therapeutic breadth.

Direct peers

• OrganoTherapeutics: Swiss-based company developing human iPSC-derived brain organoids for CNS drug discovery and disease modeling — closest direct peer by technology (brain organoids) and customer base (pharma/biotech CNS programs).
• Netri: France-based organ-on-chip and neural organoid company providing industrial-grade microfluidic brain models for pharma drug screening — comparable by offering microfluidic neural models for CNS drug discovery services.
• Neuroservice: Specialized CRO offering in vitro and in vivo CNS electrophysiology and pharmacology services to pharma — comparable as a CNS-focused discovery services provider, though its core modality is electrophysiology rather than organoids.
• InSphero: Swiss provider of 3D organoid and organ-on-chip models used for drug discovery and safety testing — directly comparable as an organoid-platform business selling into pharma with high-throughput assay services.
• Mimetas: Dutch organ-on-chip company with microfluidic 3D tissue models for drug development including neurological applications — comparable as a microfluidic organoid platform serving pharma with disease-modeling services.
• CN Bio: UK-based organ-on-chip company providing single- and multi-organ microphysiological systems for drug discovery — comparable as a human-relevant in vitro platform targeting pharma R&D, overlapping on CNS and safety applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/brainzell

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrainZell